Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program
Brett King(Yale University), Alexandre Lejeune(Pfizer (France)), Stephen Goodrich(Pfizer (United States)), Bianca Maria Piraccini(Azienda USL di Bologna), Dalia Wajsbrot(Pfizer (United States)), Rodney Sinclair(The University of Melbourne), Manabu Ohyama(Kyorin University), Lidia Rudnicka(Medical University of Warsaw), Robert Wołk(Pfizer (United States)), Helen Tran(The University of Texas Medical Branch at Galveston), Wenyu Wu(Fudan University), Sérgio Vañó-Galván(Instituto Cajal)
Cited by 0
Related Papers
Characterization and isolation of stem cell-enriched human hair follicle bulge cells
|Journal of Clinical Investigation|2005|617
Development and validation of the International Hidradenitis Suppurativa Severity Score System ( <scp>IHS</scp> 4), a novel dynamic scoring system to assess <scp>HS</scp> severity
|British Journal of Dermatology|2017|467
Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue
|Molecular Brain|2012|392
European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes
|Journal of the European Academy of Dermatology and Venereology|2017|262